ZYBERNO
Stock Report
Updated Aug 29, 2026

INSMED INC (INSM)

Healthcare • NASDAQ

$118.07
Insmed Incorporated is an American biopharmaceutical company headquartered in Bridgewater, New Jersey, focused on developing transformative therapies for patients with serious lung diseases. The company's lead product Arikayce (amikacin liposome inhalation suspension) is approved for lung disease caused by refractory Mycobacterium avium complex (MAC), and its pipeline includes brensocatib for non-cystic fibrosis bronchiectasis.

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
29.0/100
POOR BUSINESS
INSMED INC (INSM) scores 29/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-111.3%)
Debt-to-Equity (Solvency Risk):AVERAGE (0.76x)
Operating Margin (Operational Efficiency):CRITICAL (-73.9%)
Return on Capital (Capital Efficiency):CRITICAL (-53.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

INSMED INC (INSM) stock report — Zyberno Score 29/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, INSM generated -$902.48M in Owner Earnings. Capital was deployed as follows: $25.97M invested in capital expenditures. Reinvestment rate: -4.2%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:118.07
Market Cap:$25.66B

Valuation Multiples (3)

P/B Ratio:33.88x
P/S Ratio:22.56x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$26.09B

Price Action & Momentum (3)

Momentum Percentile:47 / 100
% of 52-Week High:55.5%
B. Profitability Assessment

Return Metrics (5)

ROA:-39.8%
Reinvestment Rate:-4.2%
Fundamental Growth Rate (g):2.2%

Margin Analysis (3)

Operating Margin Ttm:-73.9%
Net Margin Ttm:-76.9%
Ebitda Margin:-71.9%

TTM Performance (3)

Gross Margin Ttm:83.5%
Operating Margin Ttm:-73.9%
Net Margin Ttm:-76.9%

Yield Metrics (2)

Earnings Yield:-$3.49
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:96.7%
Latest Earnings Filed:2026-08-06

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):54.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.72x
Quick Ratio:3.40x
Cash Ratio:1.24x

Leverage Analysis (3)

Debt To Equity Ttm:0.76x
Debt-to-Equity Ratio:0.76x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-15.33x
Times Interest Earned:-15.33

Capital Structure (4)

Working Capital:1,195,175,000.00
Cash And Cash Equivalents:544,765,000.00
Long Term Debt:$543.51M
Net Debt:$427.68M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $1.14B
Linear Growth: 54.0%
📊 Click to view full INSM Revenue analysis & methodology →
Cost Of Revenue Ttm:$188.22M

Profitability Breakdown (2)

Gross profit TTM: $949.42M
Linear Growth: 55.8%
📊 Click to view full INSM Gross Profit analysis & methodology →
-$840.62M

Bottom Line Performance (3)

-$875.31M
Income Before Tax:-$869.11M
Ebitda Ttm:-817,420,000.00

Operating Expenses (5)

Operating Expenses:1,978,256,000.00
R And D Expense:860,845,000.00
Sga Expense:893,585,000.00
Income Tax Expense:$6.21M
Interest Expense:81,336,000.00

Expense Ratios (3)

R And D To Revenue Percentage:202.3%
Sga To Revenue Percentage:210.0%
Ebitda Margin:-71.9%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$2.10B
Current Assets:$1.63B
Ppe Net:107,219,000.00
Goodwill:136,110,000.00
Intangible Assets:$93.49M

Liability Structure (4)

Total Liabilities:1,345,071,000.00
Current Liabilities:438,744,000.00
Long Term Debt:$543.51M
Short Term Debt:$428.93M

Equity & Capital (3)

Equity:$757.49M
Retained Earnings:-$5.81B
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:215,325,000.00
Inventory:142,384,000.00
Accounts Payable:428,929,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:45,754,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$895.66M-$921.64M

Investment Activities (2)

Investing Cash Flow:$265.52M
Capital Expenditures Ttm:25,971,000.00

Financing Activities (3)

Financing Cash Flow:$29.51M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:377,700,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:23,201,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-4.12
-$4.12
Earnings Per Share Ttm:-$4.03

Revenue & Cash Per Share (2)

Sales Per Share Ttm:5.23
Operating Cash Flow Per Share:-$4.30

Book Value & Capital (2)

Book Value Per Share:$3.49
Cash Per Share:2.51

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.52x
Working Capital Turnover Ttm:0.95x

Receivables Management (2)

Receivables Turnover Ttm:5.28x
Days Sales Outstanding Ttm:69.09

Inventory Management (2)

Inventory Turnover Ttm:1.32x
Days Inventory Outstanding Ttm:276.12

Payables & Cash Cycle (2)

Days Payable Outstanding:831.80
Cash Conversion Cycle:-486.60
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$902.48M

Damodaran Growth Analysis (2)

Reinvestment Rate:-4.2%
Fundamental Growth Rate (g):2.2%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):54.0%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):55.8%
Book Value Growth Rate (Linear):91.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:INSM
Company Name:INSMED INC
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:high
Volume Category:N/A

Share Structure (3)

Shares Outstanding:217.35M
Shares Outstanding Basic:217.35M
Shares Outstanding Diluted:217.35M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-29 00:32:27 UTC
Data Timestamp:2026-08-29T00:32:27.510939
Scroll to Top